Lv1
100 积分 2024-12-21 加入
Effect of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors on Lipoprotein(a) Levels: An Umbrella Review of Meta-analyses of Randomized Controlled Trials
25天前
已完结
Lipoprotein(a) Reduction with Inclisiran, Alirocumab, Evolocumab, Enlicitide and Lerodalcibep: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
1个月前
已完结
Pharmacological rationale for the very early treatment of acute coronary syndrome with monoclonal antibodies anti-PCSK9
2个月前
已完结
ANGPTL3 inhibition, dyslipidemia, and cardiovascular diseases
2个月前
已完结
Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study
4个月前
已完结
Efficacy and safety of ongericimab given by prefilled syringe or autoinjector in primary hypercholesterolemia and mixed hyperlipidemia
4个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial
4个月前
已完结
Recaticimab in adult heterozygous familial hypercholesterolaemia (REMAIN-3): a multicentre, randomized, double-blind, placebo-controlled Phase 3 study
4个月前
已完结
Efficacy and safety of ongericimab in Chinese patients with heterozygous familial hypercholesterolemia: A randomized, double-blind, placebo-controlled phase 3 trial
4个月前
已完结
皖公网安备34019202002308
